Featured Pharma Online Editorial
-
Combination Products: US And EU Requirements And Harmonization
3/6/2025
In the U.S. and the EU, there are differences in the terminology used for combination products, as well as in the format and location of the information in the dossiers. This article also proposes a harmonized approach for CTD Module 3.
-
What FDA Draft Guidance Tells Us About In-Process Control Strategies
2/28/2025
The draft aims to modernize the regulations in 21 CFR 211.110 catching up to progress in the field including advanced manufacturing and analytical technologies.
-
Strengthening Shop-Floor QA From The Ground Up
2/24/2025
Quality is created where and when manufacturing happens, not later through inspection. This approach integrates the QA function into daily production operations.
-
FDA Issues Draft Guidance On The Use Of AI To Support Regulatory Decision-Making For Drug And Biological Products
2/14/2025
The U.S. FDA issued a draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, on January 6, 2025. The public comment period ends April 7.
-
Ensuring Repeatable, Viable Surface Sampling In Aseptic Settings
2/14/2025
Without high quality data, surface sampling simply becomes another exercise in checking regulatory compliance boxes.
-
GDUFA And Facility Readiness: A New Era for Generic Drug Approvals
2/13/2025
2025 marks the midpoint of the current Generic Drug User Fee Amendments (GDUFA) III program, so it's a good time to refresh yourself with requirements and facility readiness.
-
FDA Finalizes Guidance On The Advanced Manufacturing Technologies Designation Program
2/10/2025
The FDA released final guidance on the Advanced Manufacturing Technologies Designation Program at the end of December. This article shares a summary, analysis, and how it compares to the 2023 draft.
-
These Were FDA's Top Citation Issues For Data Quality In 2024
1/31/2025
Pharma, biopharma, and medical device makers should watch out for these perennial problems, which include inadequate procedural controls and poor record-keeping.
-
2024 Trends In FDA Observations For Sterile Drug Manufacturers
1/30/2025
This data-driven analysis of the 2024 trends in FDA observations for sterile drug manufacturers includes a comparison to the 2023 trends. Which 21 CFR 211 sections surprise you most?
-
Top 10 Data Auditor Statistical Software Requests
1/27/2025
Statistical analysis provides a backbone for establishing critical process parameters and offers evidence of process validation for regulatory submissions.